Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    



FDA Asks Endo Pharma to Pull Opana ER


 

In a highly unusual move, the U.S. Food and Drug Administration has requested Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. In a release on June 8, the agency said it is seeking removal based on concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.

"We are facing an opioid epidemic - a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," said FDA Commissioner Scott Gottlieb, MD. "We will continue to take regulatory steps when we see situations where an opioid product's risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse."

The FDA's decision is based on a review of all available postmarketing data, which demonstrated a significant shift in the route of abuse of Opana ER from nasal to injection following the product's reformulation. Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatitis C, as well as cases of a serious blood disorder (thrombotic microangiopathy). This decision follows a March 2017 FDA advisory committee meeting where a group of independent experts voted 18-8 that the benefits of reformulated Opana ER no longer outweigh its risks.

Opana ER was first approved in 2006 for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. In 2012, Endo replaced the original formulation of Opana ER with a new formulation intended to make the drug resistant to physical and chemical manipulation for abuse by snorting or injecting. While the product met the regulatory standards for approval, the FDA determined that the data did not show that the reformulation could be expected to meaningfully reduce abuse and declined the company's request to include labeling describing potentially abuse-deterrent properties for Opana ER. Now, with more information about the risks of the reformulated product, the agency is taking steps to remove the reformulated Opana ER from the market.

"The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak. When we determined that the product had dangerous unintended consequences, we made a decision to request its withdrawal from the market," said Janet Woodcock, MD, director of the FDA's Center for Drug Evaluation and Research. "This action will protect the public from further potential for misuse and abuse of this product."

The FDA has requested that the company voluntarily remove reformulated Opana ER from the market. Should the company choose not to remove the product, the agency intends to take steps to formally require its removal by withdrawing approval. In the interim, the FDA is making healthcare professionals and others aware of the particularly serious risks associated with the abuse of this product.

The FDA will continue to examine the risk-benefit profile of all approved opioid analgesic products and take further actions as appropriate as a part of our response to this public health crisis.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

 
Share:

Related Articles:


Recent Articles

Breakfast Celebrating the Women to Watch Class of 2017 Huge Success

Nashville Medical News' Women to Watch 2017 Breakfast celebrating 10 incredible women making a difference in healthcare was a sold out event.

Read More

HIT Parade: News from Healthcare's Tech Sector

Read More

Trial Tests Implantable Device to Ease GERD

For more than a dozen years Buz Harrison, a Nashville-based media producer, has been plagued by gastroesophageal reflux disease (GERD).

Read More

VUMC Studying Potential Approach to Reverse Precancerous Stomach Lesions

Vanderbilt University Medical Center (VUMC) cancer researcher James Goldenring, MD, PhD, has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New York, to begin clinical trials of a potential approach for reversing precancerous stomach lesions.

Read More

Attention Now Turns to the Senate for Healthcare Reform

On May 15, the American Medical Association (AMA) urged Senate leaders to keep in mind patients at risk of losing their insurance coverage. "Significant changes to the ACA or Medicaid program potentially threaten the ability for millions of Americans to obtain and retain coverage. It is these citizens, constituents, and patients who should be at the center of this debate," wrote AMA CEO James L. Madara, MD.

Read More

The New Face of Aesthetic Medicine

Aesthetic medicine procedures have become increasingly popular, but not all procedures ... or practices ... are created equal.

Read More

Pioneering Sexual Health

Meharry professor Dr. Kevin Billups is a pioneer in the field of men's health.

Read More

Moving at Light Speed

No longer the stuff of science fiction, lasers and radio frequency are improving skin care one patient at a time.

Read More

Disappearing Ink

When that really awesome tattoo isn't so awesome anymore, patients now have access to new technology that makes removal much easier.

Read More

Something to Smile About

Receding gum lines can damage more than self-esteem, but a procedure now available in Nashville is offering hope to patients suffering from a common dental concern.

Read More

Email Print
 
 

 

 


Tags:
Drug Abuse, Endo Pharmaceuticals, FDA, Food and Drug Administration, Opana ER, Opioid Addiction
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: